Weight-loss drug retatrutide tested on kidney patients: 14 kg loss in six months
Published
Retatrutide, a new drug, is considered one of the most talked-about medications in the world of weight loss. In recent years there has been a great deal of interest in drugs of this kind, and in Israel too, many people ask their doctors and health maintenance organizations about them.
The new drug works differently from other drugs. Mounjaro acts on two hormones in the body, while Ozempic acts on one hormone. According to reports, retatrutide was tested on patients who suffer from kidney problems. Over the course of six months, the participants in the trial lost about 14 kilograms in weight.
It is important to know that these results are still at the trial stage. In order to know whether the drug is safe and effective for the general public, it needs to be tested for a longer period. Therefore, the drug is not yet available to everyone who wants to buy it.
In summary, retatrutide is a drug that is generating great interest around the world. The research on kidney patients shows interesting results, but experts recommend waiting for more information before relying on it. Anyone considering weight-loss treatment should speak with their doctor.
Sources: היום
More Israel news
- Israel and France Explore New Approaches to Mental Health Care
- Sudden Facial Paralysis and Diabetes: What a New Israeli Study Shows
- A U.S. Medical Delegation Visited Laniado Hospital in Netanya
- A Special Crossing Over Route 6: A Bridge for Wildlife
- Revolut Receives Conditional License to Establish a Bank in Israel
- Ministry of Health Cancels Water Boiling Order in Kfar Chabad
- Eisenkot and opposition leaders agree on candidates for key Knesset positions
- Exiled Iranian Prince: Iran Is Likely to Use Nuclear Weapons Against Israel